Skip to main content
SpringerLink
Log in

The status of Chinese medicine in reversing multi-drug resistance of hepatocellular carcinoma

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Multi-drug resistance (MDR) is a major obstacle in the chemotherapy of hepatocellular carcinoma. Comparing with western reversal agents, traditional Chinese medicine have advantages of low cost, hypotoxicity, wide safety range, broad-spectrum and multi-targets, etc. Therefore, traditional Chinese medicine may be expected to open up a new path to reverse MDR of liver cancer. Studies about applying traditional Chinese medicine to reverse MDR in hepatocellular carcinoma are outlined below.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 2007, 132: 2557–2576.

    Article  PubMed  CAS  Google Scholar 

  2. Gish RG, Baron A. Hepatocellular carcinoma (HCC): current and evolving therapies. Drugs, 2008, 11: 198–203.

    CAS  Google Scholar 

  3. Jin XS, Gen XP, Zhu LX. Progress of hepatocellular carcinoma multidrug resistance. J Hepatobiliary Surg (Chinese), 2007, 15: 234–236.

    Google Scholar 

  4. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci, 2008, 65: 3145–3167.

    Article  PubMed  CAS  Google Scholar 

  5. Zhu H, Chen XP, Luo SF, et al. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells. J Exp Clin Cancer Res (Chinese), 2005, 24: 565–574.

    CAS  Google Scholar 

  6. Luo SF, Chen XP, Zhu H, et al. Glucose deprivation and formation of multidrug resistance of hepatocellular carcinoma. Chin J Exp Surg (Chinese), 2007, 24: 182–184.

    CAS  Google Scholar 

  7. Doong SL, Lin MH, Tsai MM, et al. Transactivation of the human MDR1 gene by hepatitis B virus X gene product. J Hepatol, 1998, 29: 872–878.

    Article  PubMed  CAS  Google Scholar 

  8. Yang SL, Chen XP, Zhang WG. Hepatitis B virus X protein induces the up-regulation of MDR expression by activation of NF-κB signaling pathway. Chin J Exp Surg (Chinese), 2008, 25: 1603–1605.

    CAS  Google Scholar 

  9. Pari L, Tewas D, Eckel J. Role of curcumin in health and disease. Arch Physiol Biochem, 2008, 114: 127–149.

    Article  PubMed  CAS  Google Scholar 

  10. Wei M, Zhang YD, He JT. Reversion of drug resistance in a hepatocellular carcinoma by curcumine in vitro. Chin J Mod Med (Chinese), 2008, 18: 2441–2448.

    CAS  Google Scholar 

  11. Liao YQ, Li WH, Liu YZ. Study on antitumor effect of Ligustrazine. Pract Clin J Integr Tradit Chin West Med (Chinese), 2007, 7: 92–93.

    Google Scholar 

  12. Wang XB, Wang SS, Zhang QF, et al. Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep, 2010, 23: 211–215.

    PubMed  CAS  Google Scholar 

  13. Liu Y, Li RS, Wang SS, et al. Effects of tetramethylpyrazine on the accumulation of doxorubicin in human drug resistant hepatocellular carcinoma cells Bel-7402/DXR. Herald Med (Chinese), 2009, 5: 92–93.

    Google Scholar 

  14. Zhang LH, Chen BE, Pan MJ. New progress of pharmacological effects of matrine. Chin Tradit Herbal Drugs (Chinese), 2009, 40: 1000–1003.

    CAS  Google Scholar 

  15. Xu XY, He S. Experimental study of matrine to reverse drug-resistance of human multidrug-resistance hepatoma carcinoma cell. J Chongqing Med Univ (Chinese), 2008, 33: 411–415.

    CAS  Google Scholar 

  16. Chen ZR. An overview of clinical application of tetrandrine. Strait Pharm J (Chinese), 2008, 20: 119–121.

    Google Scholar 

  17. Sun Y, He KJ. Effect of tetredrine (TTD), raloxifene and their combination on reversion of multidrug resistance of human hepatocellular carcinoma (HCC) multidrug resistant cell line (Hep-3B/ADM). Chin J Misdiagn (Chinese), 2009, 9: 8071–8073.

    CAS  Google Scholar 

  18. Xu M. Study Progress of Epigallocatechin gallate. Chin J Tradit Med Sci Technol (Chinese), 2008, 15: 485–486.

    CAS  Google Scholar 

  19. Tang HH, Zhou M, Liang G. Impact of epigallocatechin gallate on gene expression profiles of human hepatocellular carcinoma cell lines BEL7404/ADM and BEL7402/5-FU. Chin J Cancer (Chinese), 2008, 27: 1056–1064.

    CAS  Google Scholar 

  20. Wen M, Li X, Fu ST. New progress of pharmacological effects of Baicalin. J Shenyang Pharm Univ (Chinese), 2008, 25: 158–162.

    CAS  Google Scholar 

  21. Guo X, Guo Y. Inhibitory effect of baical in on fluorouracil resistant HCC cell line BEL-7402/5-FU and its possible mechanism. Acad J Second Mil Med Univ (Chinese), 2008, 29: 24–29.

    Article  CAS  Google Scholar 

  22. Tang XQ, Cao JG. Pharmacological effects of liensinine. Chin Pharm Bull (Chinese), 2004, 20: 8–10.

    CAS  Google Scholar 

  23. Ai XH, Tang XQ, Liu YP, et al. Effect of neferine on adriamycin-resistance of thermotolerant hepatocarcinoma cell line HepG2/thermotolerance. Chin J Cancer (Chinese), 2007, 26: 357–360.

    CAS  Google Scholar 

  24. Zhang Q, Zhao WJ, Wang JW. Progress on harmacological effects and clinical application of Scorpion. Inf Tradit Chin Med (Chinese), 2006, 23: 26–28.

    Google Scholar 

  25. Yang CX, Wei XM, Zhu L, et al. Study on reversing effect of scorpion venom to liver cancer resistant-drug cell line Bel-7404/ADM. J Guangxi Med Univ (Chinese), 2007, 24: 243–245.

    CAS  Google Scholar 

  26. Tang JY, Chen P. The mechanism of anticarcinoma by arsenic trioxide (ATO) and the relationship between ATO and radiosensitivity and Chemosensitivity. J Xinxiang Med Coll (Chinese), 2007, 24: 422–425.

    CAS  Google Scholar 

  27. Zhang XW, Yan XJ, Zhou ZR, et al. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science, 2010, 328: 240–243.

    Article  PubMed  CAS  Google Scholar 

  28. Li H, Xiong MM, Meng XL, et al. Reversing effect of arsenic trioxide on multidrug resistance of human hepatocellular carcinoma HepG2/ ADM cells. World Chin J Digestol (Chinese), 2006, 14: 2691–2694.

    CAS  Google Scholar 

  29. Li YH, Zhu KL, Zeng WT. Reversal of drug resistance of hepatocellular carcinoma cells by arsenic trioxide (As2O3). Clin Med Eng (Chinese), 2009, 16: 8–10.

    Google Scholar 

  30. Zou H, Gong CC, Jin LY, et al. Experimental study on arsenic trioxide inducing apoptosis of hepatoma multidrug resistance cell BEL-7402/ ADM. Chin J Gerontol (Chinese), 2007, 22: 2207–2208.

    Google Scholar 

  31. Wang N, Li Y, Liu J, et al. Experimental study on arsenic trioxide inducing apoptosis of hepatoma mltidrug resistance cells. Chin J Lab Diagn (Chinese), 2007, 11: 954–956.

    Google Scholar 

  32. Liu S, Song Y, Li J, et al. Advances in the study on the mechanism of Quercetin’s biological action. Mod Prev Med (Chinese), 2009, 36: 2837–2839.

    CAS  Google Scholar 

  33. Zhang RX, Chen XJ, Wang SJ, et al. Study on reversion effect of quercetin on drug-resistance of human liver cancer cell SMMC7721/ VCR. Acta Acad Med Jiangxi (Chinese), 2008, 48: 25–27.

    Google Scholar 

  34. Yi X, Chen ZW. New progress of cantharidin and its pharmacological effects. Life Sci Instruments (Chinese), 2009, 7: 3–6.

    Google Scholar 

  35. Zheng LH, Bao YL, Wu Y, et al. Cantharidin reverses multidrug resistance of human hepatoma HepG2/ADM cells via down-regulation of P-glycoprotein expression. Cancer Lett, 2008, 272: 102–109.

    Article  PubMed  CAS  Google Scholar 

  36. Huang JD. An overview of Isatis chemical composition and its pharmacological effect. Chin J Mod Drug Appl (Chinese), 2009, 3: 197–198.

    Google Scholar 

  37. Hou HX, Li DR, Wei CY, et al. The reverse roles of unsaturated fatty acids from Isatis tinctoria L on human multidrug-resistant hepatocellular carcinoma cell BEL-7404/ ADM. Chin J Mod Drug Appl (Chinese), 2002, 19: 351–353.

    Google Scholar 

  38. Wei CY, Li DR, Jiang B, et al. Experimental study of Isatis tinctoria L conbination acid active single-body-5b reversing the drug-resistant of hepatocellular carcinoma cell. Chin J Cancer Prev Treat (Chinese), 2003, 10: 580–582.

    CAS  Google Scholar 

  39. Wei CY, Li DR, Qin J, et al. The study of Isatis tinctiorial combinnation acid reversing the drug-resistant of transplanted tumor of human hepatocellular carcinoma in situ. J Hepatobiliary Surg (Chinese), 2004, 12: 334–337.

    Google Scholar 

  40. Jiang B, Liu QL. The reverse role of the activity of banlangen to human multidrug-resistant hepatocellular carcinoma cells. J Jining Med Coll (Chinese), 2004, 27: 11–13.

    Google Scholar 

  41. Niu XR. An Overview of Bupleurum’s pharmacological effect. Chin Pharm (Chinese), 2009, 12: 1310–1312.

    Google Scholar 

  42. Gai XD, Zeng CQ, Hong M. Effect of Bupleurun Chinese DC (BCDC) on the MDR reversal of hepatocellular carcinoma and related mechanism. Chem J Chin Univ (Chinese), 2005, 26: 1446–1450.

    CAS  Google Scholar 

  43. Zhu JQ, Han XG, Xue YJ. Effects of the extracts from BCDC on cellular VCR concentration of human hepatoma BEL-7402 cells. J Beihua Univ (Natural Science Edition) (Chinese), 2005, 6: 62–64.

    CAS  Google Scholar 

  44. Han XH, Gai XD, Xue YJ, et al. Effects of the extracts from Bupleurum Chinese DC on intracelluar free calcium concentration and vincristine accumulation in human hepatoma BEL-7402 cells. Tumor (Chinese), 2006, 26: 314–317.

    Google Scholar 

  45. Fan JJ. Anti-tumor role of stellera chamaejasme L and research of its’ mechanisms. J Clin Res (Chinese), 2007, 24: 2001–2003.

    Google Scholar 

  46. Ma J, Li YH, Luo JB, et al. The study of the co-action of Stellera chamaejasme L (SL) and chemotherapy drug to induce the necrosis of drug-resistant liver carcinoma cell. Acta Chin Med Pharm (Chinese), 2007, 35: 15–16.

    Google Scholar 

  47. Liu C, Zhu HJ. Current research of Schisandrin. Chin Med Herald (Chinese), 2007, 4: 15–16.

    Google Scholar 

  48. Huang M, Jin J, Sun H, et al. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol, 2008, 62: 1015–1026.

    Article  PubMed  CAS  Google Scholar 

  49. Wan CK, Zhu GY, Shen XL, et al. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol, 2006, 72: 824–837.

    Article  PubMed  CAS  Google Scholar 

  50. Jiang XQ. Clinical application of Astragulus. Chin J Clin Rational Drug Use (Chinese), 2010, 3: 76.

    Google Scholar 

  51. Zhang JK, Wang ZY, Ding DP, et al. Effect of Astragulus injection on chemosensitivity of drug-resistant hepatic carcinoma Bel/Fu cell line. Chin J Surg Inte (Chinese), 2008, 14: 398–402.

    CAS  Google Scholar 

  52. Li Q, Liu ZJ, Zhang J, et al. The effects of GanAi-1 on the reversal of multidrug resistance in hepcatocellular carcinoma. J Digest Surg (Chinese), 2006, 5: 70–73.

    Google Scholar 

  53. Gu W, Zhai XF, Zhang YN, et al. In vitro study of Ganli injection on reversing acquired multidrug resistance of human hepatocellular carcinoma. Chin Tradit Herbal Drugs (Chinese), 2007, 38: 871–874.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General Surgery, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430077, China

    Shengli Yang, Yunxia Wang, Xiaoli Pan & Zhifan Xiong

Authors
  1. Shengli Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yunxia Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoli Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Zhifan Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhifan Xiong.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, S., Wang, Y., Pan, X. et al. The status of Chinese medicine in reversing multi-drug resistance of hepatocellular carcinoma. Chin. -Ger. J. Clin. Oncol. 10, 541–546 (2011). https://doi.org/10.1007/s10330-011-0828-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-011-0828-1

Key words

Search

Navigation